ClinicalTrials.gg
RecruitingNCT05684653Updated Sep 21, 2023

Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject

A Phase 1 interventional study of Orelabrutinib Tablets in Hepatic Impairment, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 4 sites in China. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years to 79 Years
Sex
All
01

Study summary

This is an Open-Label, Parallel, Single-dose, Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of Orelabrutinib Tablets in Subjects with Varying Degrees of Hepatic Impairment

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject understands and has provided the form (ICF);
  2. Male and female between 18 and 79 years old (inclusive) at the time of signing the ICF;
  3. Male with weight not less than 50 kg and female not less than 45 kg. (BMI): 18-32 kg/m2 (inclusive);
  4. The subject is suitable to participate in the study as evaluated by the investigator based on physical examination, vital signs, laboratory tests, and 12-lead ;
  5. Within 2 weeks before the study medication, the subject took no prohibited drug (see Appendix 4 for the drugs), including any prescription drug, OTC drug, Chinese herbal medicine, or dietary supplement;
  6. The subject is willing to take effective voluntarily from the screening to 3 months after the dosing of study drug;

The following criteria apply to the subjects with hepatic impairment:

Patients with chronic hepatic impairment resulted from viral hepatitis, alcoholic liver disease, hepatitis, or other causes. Patients with chronic hepatic impairment are defined as patients with a history of hepatic impairment and stable liver functions for ≥ 1 month based on clinical manifestations. For patients with viral hepatitis, it is imperative to exclude active (if the patient was tested HCV antibody positive, at least 2 tests within 3 months indicating HCV-RNA negative are required) and active (HBV-DNA level should be less than 100 IU/mL with concurrent antiviral treatment); or patients with hepatic cirrhosis confirmed by liver or other medical imaging (including laparoscopy, computed tomography (CT), magnetic resonance imaging (MRI), or ultrasonography); or patients with diagnosed hepatic cirrhosis complicated with portal hypertension (allow receiving related portal hypotensives treatments, e.g., carvedilol). Patients who meet any of the above conditions can participate in this study.

  1. Hepatic impairment of Class A or Class B or Class C based on system (no albumin should be used within 14 days); and resulted from prior primary liver disease; 9. Coagulation functions: ≤2.5 without intervention of coagulants (2-week washout); hematology: ≥ 1.5 × 109/L, ≥ 70 g/L, count ≥30 × 109/L; hepatic function: (ALT) and aspartate aminotransferase (AST) ≤ 5 × (ULN); 10. Stable therapy for hepatic impairment before the study medication, and at least 4-week stable medication for treatment of hepatic impairment (stable medications were judged by the investigator); 11. The subject agrees to abstain from smoking, alcohol, caffeinated beverages, and fruit juice beverages from 7 days before the study medication to the end of study follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Drug-induced liver injury;
  2. Acute hepatic impairment due to various causes;
  3. Any of the following circumstances: liver transplant recipients; acute or exacerbating hepatic impairment due to various causes; liver failure, complicated with grade 3/4 hepatic encephalopathy; active lesions of hepatic cancer; esophageal and gastric varices hemorrhage; serious/advanced peritoneal or pleural effusion requiring puncture drainage and albumin supplementation; situations deemed not suitable to participate in the study including hepatorenal syndrome;
  4. Diseases influencing bile excretion within 3 months before the screening, including cholestatic liver disease or biliary tract infection;
  5. Subjects having portal hypertension with esophageal and gastric varices bleeding within 3 months or subjects having received portal-systemic shunt procedure within half a year, including transjugular intrahepatic portosystemic shunt (TIPS);
  6. History of significant allergy or intolerance to any drug, food, or other substance;
  7. Patients with abnormal test value which is clinical significance at screening or before enrollment, that influence the evaluation of safety, including physical examination, vital signs, routine laboratory tests (hematology, blood biochemistry, coagulation function, and urinalysis), 12-lead , and chest CT;
  8. Any history of serious disease or tother conditions that may influence the study findings, including but not limited to disorders of nervous, cardiovascular, hematologic and lymphatic, immune, renal, gastrointestinal, respiratory, endocrine systems;
  9. History of surgery that may influence drug absorption, distribution, metabolism, or excretion (e.g., gastroduodenectomy), or proposed possible surgery or scheduled hospitalization during the study;
  10. Clinical manifestations of bacterial, viral, parasitic, or fungal infection requiring treatment, and coronavirus infection or nucleic acid test positive at screening (excluding ) or history of serious active infection within 1 month before the screening;
  11. Human immune-deficiency virus () antibody positive or active syphilis at screening;
  12. Anticoagulation therapies including warfarin or thrombin inhibitors and/or antiplatelet therapy with aspirin within 1 month before the screening;
  13. Administration of inhibitors or inducers of drug metabolism in the liver, administration of sensitive P-gp and BCRP substrates with narrow therapeutic index within 2 weeks (or 5 half-lives, whichever longer) before the screening;
  14. Drug abuse or history of soft drugs within 3 months before the screening or history of hard drugs within 1 year before the screening; or urine drug test positive at screening;
  15. Mean daily consumption of more than 5 cigarettes or habitually consumption of nicotine-containing products , mean daily alcohol intake exceeds the criteria within 3 months before the screening with failure to abstain from smoking or or cannot abstain from alcohol during the trial;
  16. Intake of grapefruit juice, methylxanthine-rich food or beverages (e.g., coffee, tea, cola, chocolates, and energy drinks) within 7 days before taking the study medication, or strenuous exercise or any other factor influencing drug absorption, distribution, metabolism, and excretion, with failure to abstain from during the trial;
  17. Those who participated in clinical trials of any other study drug or medical device within 3 months before the first dose of the study drug, or participated in 3 or more clinical trials of drugs or medical devices within the latest year; for other study drugs with a long half-life, a longer time interval is required for at least 5 half-lives of the drug;
  18. Blood donation (or lost) ≥ 400 mL within 3 months before the screening, or blood transfusion recipients or blood product users;
  19. Vaccination within 4 weeks before the screening or scheduled vaccination during the trial;
  20. Women in lactation or with serum pregnancy test positive at screening;
  21. Birth plan scheduled from screening to 3 months after trial completion, or unwilling to take rigorous from screening to 3 months after study completion, or proposed scheduled sperm donation;
  22. Unwilling or Unable to abide by the study procedure specified in the protocol, or has any factor deemed unsuitable for participating in this clinical study by the investigator.

    The following exclusion criteria apply to subjects with normal hepatic function:

  23. History of hepatic impairment, or presence of possible hepatic impairment at screening as suggested by physical examination and laboratory tests; HBsAg-positive or anti- antibody-positive.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Orelabrutinib Tablets

    Subjects take Single dose of 50 mg orelabrutinib tablet under fasting state

    Drug: Orelabrutinib Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve from time 0 to infinity (AUC0-∞) (Blood)

    Time frame: Blood samples for pharmacokinetics will be taken on Day 1 at pre dose, at 30 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours post dose.

  2. Area under the concentration-time curve from time 0 to infinity (AUC0-t) (Blood)

    Time frame: Blood samples for pharmacokinetics will be taken on Day 1 at pre dose , at 30 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours post dose.

  3. Maximum concentration(Cmax) (Blood)

    Time frame: Blood samples for pharmacokinetics will be taken on Day 1 at pre dose, at 30 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours post dose.

Secondary outcomes

  1. Time to maximum concentration(Tmax)(Blood)

    Time frame: Blood samples for pharmacokinetics will be taken on Day 1 at pre dose, at 30 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours post dose.

  2. Half-Life (T1/2) (Blood)

    Time frame: Blood samples for pharmacokinetics will be taken on Day 1 at pre dose, at 30 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours post dose.

  3. Apparent Volume of Distribution (Vz/F) (Blood)

    Time frame: Blood samples for pharmacokinetics will be taken on Day 1 at pre dose, at 30 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours post dose.

  4. Apparent clearance (CL/F) (Blood)

    Time frame: Blood samples for pharmacokinetics will be taken on Day 1 at pre dose, at 30 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours post dose.

  5. Unbound maximum concentration (Cmax, unb) (Blood)

    Time frame: Blood samples for pharmacokinetics will be taken on Day 1 at pre dose, at 30 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours post dose.

  6. Area under the unbound drug concentration-time curve (AUCunb) (Blood)

    Time frame: Blood samples for pharmacokinetics will be taken on Day 1 at pre dose, at 30 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48hours post dose.

  7. AEs

    Time frame: Through study completion, an average of 1 year

  8. SAEs

    Time frame: Through study completion, an average of 1 year

07

Study locations

2 of 4 sites recruiting
  • The First Affilitaed Hospital of Bengbu Medical College
    Bengbu, Anhui, China
    Not yet recruiting
    • Huan Zhou · Contact
    • Yu Zhu · Contact
  • The First Affilitaed Hospital of Soochow University
    Suzhou, Jiangsu, China
    Recruiting
    • Liyan Miao · Contact
    • Weifeng Zhao · Contact
  • Deyang People's Hospital
    Deyang, Sichuan, China
    Recruiting
    • Lianlian Fan · Contact
    • Shunbin Ding · Contact
  • Shulan (Hangzhou) hospital
    Hangzhou, Zhejiang, China
    Not yet recruiting
    • Lihua Wu · Contact
    • Hainv Gao · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2023 (actual). Primary completion is estimated for Dec 2023, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2022
First posted
Jan 13, 2023
StartActual
Mar 17, 2023
Primary completionEst.
Dec 30, 2023
CompletionEst.
Dec 30, 2023
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05684653
Responsible party
Sponsor
First posted
Jan 13, 2023
Start date
Mar 17, 2023
Primary completion
Dec 30, 2023 (estimated)
Completion
Dec 30, 2023 (estimated)
Last update
Sep 21, 2023

Study contacts

Liyan Miao
Contact
Sdfyy8040@126.com
86-512-67972858
Weifeng Zhao
Contact
Sdyy8040@126.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion